Commonwealth Equity Services LLC Has $2.42 Million Stock Holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Commonwealth Equity Services LLC lifted its position in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHEFree Report) by 188.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,583 shares of the company’s stock after acquiring an additional 23,230 shares during the period. Commonwealth Equity Services LLC owned approximately 0.35% of iShares U.S. Pharmaceuticals ETF worth $2,416,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of IHE. Fisher Asset Management LLC raised its position in shares of iShares U.S. Pharmaceuticals ETF by 5,567.8% in the 4th quarter. Fisher Asset Management LLC now owns 1,208,199 shares of the company’s stock valued at $224,003,000 after acquiring an additional 1,186,882 shares during the period. Accurate Wealth Management LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 1st quarter valued at approximately $7,364,000. Tower Research Capital LLC TRC raised its position in shares of iShares U.S. Pharmaceuticals ETF by 2,209.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 43,357 shares of the company’s stock valued at $8,038,000 after acquiring an additional 41,480 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in iShares U.S. Pharmaceuticals ETF by 337.2% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 16,418 shares of the company’s stock worth $3,044,000 after purchasing an additional 12,663 shares in the last quarter. Finally, Kraft Davis & Associates LLC bought a new stake in iShares U.S. Pharmaceuticals ETF during the 4th quarter worth approximately $2,144,000.

iShares U.S. Pharmaceuticals ETF Stock Performance

NYSEARCA IHE opened at $65.99 on Friday. The business has a 50 day simple moving average of $65.95 and a 200 day simple moving average of $65.51. iShares U.S. Pharmaceuticals ETF has a 52-week low of $55.36 and a 52-week high of $69.56. The stock has a market cap of $666.50 million, a price-to-earnings ratio of 6.49 and a beta of 0.58.

iShares U.S. Pharmaceuticals ETF Profile

(Free Report)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.

Featured Articles

Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHEFree Report).

Institutional Ownership by Quarter for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)

Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.